Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
L3Harris
LHX
|
$148M |
| 2 |
GE HealthCare
GEHC
|
$118M |
| 3 |
Atlassian
TEAM
|
$101M |
| 4 |
Monster Beverage
MNST
|
$81.1M |
| 5 |
PACCAR
PCAR
|
$48.1M |
Top Sells
| 1 |
Apple
AAPL
|
$360M |
| 2 |
Microsoft
MSFT
|
$199M |
| 3 |
NVIDIA
NVDA
|
$99.2M |
| 4 |
Amazon
AMZN
|
$85.4M |
| 5 |
Alphabet (Google) Class C
GOOG
|
$83.8M |
Sector Composition
| 1 | Technology | 28.64% |
| 2 | Healthcare | 14.81% |
| 3 | Consumer Discretionary | 11.76% |
| 4 | Industrials | 9.45% |
| 5 | Communication Services | 8.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2501
MiMedx Group
MDXG
$1.05B
| $544K | ﹤0.01% |
159,400
-18,900
| -11% | -$64.4K |
|
2502
SIGA Technologies
SIGA
$618M
| $543K | ﹤0.01% |
94,500
-10,600
| -10% | -$61K |
|
2503
NextDecade
NEXT
$2.8B
| $542K | ﹤0.01% |
109,100
-9,900
| -8% | -$49.2K |
|
2504
Atea Pharmaceuticals
AVIR
$267M
| $542K | ﹤0.01% |
161,800
-19,200
| -11% | -$64.3K |
|
2505
Vuzix
VUZI
$166M
| $541K | ﹤0.01% |
130,700
-12,200
| -9% | -$50.5K |
|
2506
Tredegar Corp
TG
$272M
| $536K | ﹤0.01% |
58,700
-6,900
| -11% | -$63K |
|
2507
Compass Therapeutics
CMPX
$474M
| $534K | ﹤0.01% |
+163,400
| New | +$534K |
|
2508
Donegal Group Class A
DGICA
$653M
| $532K | ﹤0.01% |
34,800
-3,900
| -10% | -$59.6K |
|
2509
Sangamo Therapeutics
SGMO
$163M
| $529K | ﹤0.01% |
300,660
-20,600
| -6% | -$36.3K |
|
2510
Codexis
CDXS
$227M
| $528K | ﹤0.01% |
127,600
-14,800
| -10% | -$61.3K |
|
|
LOGC
2511
DELISTED
ContextLogic
LOGC
| $521K | ﹤0.01% |
1,169,000
-7,400
| -0.6% | -$3.3K |
|
2512
Prime Medicine
PRME
$556M
| $515K | ﹤0.01% |
+41,900
| New | +$515K |
|
2513
1-800-Flowers.com
FLWS
$356M
| $511K | ﹤0.01% |
44,400
-3,500
| -7% | -$40.3K |
|
2514
South Plains Financial
SPFI
$660M
| $510K | ﹤0.01% |
23,833
-3,400
| -12% | -$72.8K |
|
|
NEWP
2515
New Pacific Metals
NEWP
$335M
| $506K | ﹤0.01% |
187,760
-15,900
| -8% | -$42.9K |
|
2516
Atara Biotherapeutics
ATRA
$86.7M
| $505K | ﹤0.01% |
174,000
-19,700
| -10% | -$57.1K |
|
2517
CarParts.com
PRTS
$45.3M
| $503K | ﹤0.01% |
94,200
-8,400
| -8% | -$44.9K |
|
2518
Cellebrite
CLBT
$4B
| $502K | ﹤0.01% |
82,500
-6,500
| -7% | -$39.6K |
|
2519
Hyliion Holdings
HYLN
$282M
| $499K | ﹤0.01% |
252,100
-21,000
| -8% | -$41.6K |
|
2520
Alkami Technology
ALKT
$2.66B
| $499K | ﹤0.01% |
39,400
-3,500
| -8% | -$44.3K |
|
|
TARO
2521
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $499K | ﹤0.01% |
20,500
-2,000
| -9% | -$48.6K |
|
|
NGMS
2522
DELISTED
NeoGames S.A. Ordinary Shares
NGMS
| $497K | ﹤0.01% |
32,730
-3,800
| -10% | -$57.8K |
|
2523
Universal Logistics Holdings
ULH
$683M
| $496K | ﹤0.01% |
17,000
-2,000
| -11% | -$58.3K |
|
2524
Nano X Imaging
NNOX
$242M
| $492K | ﹤0.01% |
85,200
-8,200
| -9% | -$47.3K |
|
2525
Douglas Elliman
DOUG
$241M
| $491K | ﹤0.01% |
157,886
-15,500
| -9% | -$48.2K |
|